The Portugal-based active pharmaceutical ingredient firm has invested in capabilities such as crystal design, particle size reduction to the micro or nano-scale and amorphous solid dispersion development.
Hovione will provide the new services for both laboratory development and commercial scale production and as part of its clinical manufacturing business.
CEO Guy Villax said: “In response to customers’ needs, Hovione is investing in new technologies, many of them capable of handling highly potent compounds. These will help drive compounds with development challenges from early clinical to market.”
This was echoed by Colin Minchom, head of Hovione’s particle design business, who stressed that the new high tech offering combined new technologies with scientific expertise.
“More than the technologies, the quality of Hovione’s scientists, engineers and their experience in the application of 21st Century methodologies such as QbD, PAT and process modelling are outstanding.”
Hovione has been putting a lot of effort into the development of solubility solutions in recent years, in recognition of the pharmaceutical industry’s growing need for delivery technologies and formulations that are effective.
In 2009 , for example Hovione bought aseptic spray drying technology from Acusphere citing growing customer demand for technologies that enhance the bioavailability of therapeutic compounds.
The process continued in 2011 when Hovione partnered with Particle Sciences (PSI) in a deal which saw it provide scale-up manufacturing services for solubilisation processes developed by the US firm.